Alkem Laboratories Limited — Important, 07-02-2025: Updates

The Board of Alkem Laboratories has approved the financial results for the quarter and nine months ended December 31, 2024, reporting consolidated revenue from operations at ₹33,742.8 million. Total income stood at ₹34,672.7 million, with a profit before tax of ₹7,310.7 million. The company declared an interim dividend of ₹37 per equity share, set for payment starting February 28, 2025. The consolidated net profit totaled ₹6,407.9 million.

On a standalone basis, revenue from operations reached ₹22,868.3 million, with total income at ₹24,560.1 million. The profit for the period was noted at ₹7,231.2 million. The company continues to navigate its strategy post the recent transfer of its Generic Business Undertaking to Alkem Wellness Limited, with no significant impact on consolidated results. Investors should note these results, reflecting strong performance with a positive outlook.